Repros Therapeutics CEO Acquires $29,211 in Stock (RPRX)
Repros Therapeutics (NASDAQ:RPRX) CEO Joseph Podolski acquired 2,100 shares of Repros Therapeutics stock on the open market in a transaction that occurred on Thursday, August 14th. The shares were purchased at an average cost of $13.91 per share, for a total transaction of $29,211.00. Following the completion of the acquisition, the chief executive officer now directly owns 61,045 shares of the company’s stock, valued at approximately $849,136. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Repros Therapeutics (NASDAQ:RPRX) traded up 1.31% on Thursday, hitting $13.94. 242,075 shares of the company’s stock traded hands. Repros Therapeutics has a one year low of $12.61 and a one year high of $29.79. The stock’s 50-day moving average is $15.28 and its 200-day moving average is $16.87. The company’s market cap is $322.0 million.
Repros Therapeutics (NASDAQ:RPRX) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.38) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.37) by $0.01. On average, analysts predict that Repros Therapeutics will post $-1.53 earnings per share for the current fiscal year.
Repros Therapeutics, Inc is a United States-based company that develops products and services for the management of reproductive health.
Receive News & Ratings for Repros Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repros Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.